Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application
M Li, L Li, J Zheng, Z Li, S Li, K Wang, X Chen - Molecular Cancer, 2023 - Springer
Renal cell carcinoma (RCC) is a major pathological type of kidney cancer and is one of the
most common malignancies worldwide. The unremarkable symptoms of early stages …
most common malignancies worldwide. The unremarkable symptoms of early stages …
Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
WM Brueckl, JH Ficker, G Zeitler - BMC cancer, 2020 - Springer
Background Immune checkpoint inhibitors (ICI) either alone or in combination with
chemotherapy have expanded our choice of agents for the palliative treatment of non-small …
chemotherapy have expanded our choice of agents for the palliative treatment of non-small …
[HTML][HTML] The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer …
A Galvano, V Gristina, U Malapelle, P Pisapia, F Pepe… - ESMO open, 2021 - Elsevier
Background The role of tumor mutational burden (TMB) is still debated for selecting
advanced non-oncogene addicted non-small-cell lung cancer (NSCLC) patients who might …
advanced non-oncogene addicted non-small-cell lung cancer (NSCLC) patients who might …
Impact of high tumor mutational burden in solid tumors and challenges for biomarker application
MG McNamara, T Jacobs, A Lamarca, RA Hubner… - Cancer treatment …, 2020 - Elsevier
Accurate identification of patients with solid tumors likely to respond to immunotherapy is
crucial. Tumor mutational burden (TMB) measures the number of somatic mutations in a …
crucial. Tumor mutational burden (TMB) measures the number of somatic mutations in a …
[HTML][HTML] Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
P Vryza, T Fischer, E Mistakidi, A Zaravinos - Translational Oncology, 2023 - Elsevier
Immune checkpoint inhibition (ICI) therapies have reshaped the therapeutic landscape in
lung cancer management, providing first-time improvements in patient response, prognosis …
lung cancer management, providing first-time improvements in patient response, prognosis …
[HTML][HTML] Assessing tumor heterogeneity: integrating tissue and circulating tumor DNA (ctDNA) analysis in the era of immuno-oncology-blood TMB is not the same as …
S Fridland, J Choi, M Nam… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Tissue tumor mutational burden (tTMB) is calculated to aid in cancer treatment selection.
High tTMB predicts a favorable response to immunotherapy in patients with non-small cell …
High tTMB predicts a favorable response to immunotherapy in patients with non-small cell …
Prognostic role of tumor mutational burden in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
T Huang, X Chen, H Zhang, Y Liang, L Li, H Wei… - Frontiers in …, 2021 - frontiersin.org
Purpose Immunotherapy is regarded as the most promising treatment for cancer. However,
immune checkpoint inhibitors (ICIs) are not effective for all patients. Herein, we conducted a …
immune checkpoint inhibitors (ICIs) are not effective for all patients. Herein, we conducted a …
[HTML][HTML] KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥ 50%) lung …
N Frost, J Kollmeier, C Vollbrecht, C Grah… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Background Pembrolizumab is a standard of care as first line palliative therapy in PD-L1
overexpressing (≥ 50%) non-small cell lung cancer (NSCLC). This study aimed at the …
overexpressing (≥ 50%) non-small cell lung cancer (NSCLC). This study aimed at the …
[HTML][HTML] Clinical and technical insights of tumour mutational burden in non-small cell lung cancer
M Meri-Abad, A Moreno-Manuel, SG García… - Critical Reviews in …, 2023 - Elsevier
Despite the durable responses provided by the introduction of checkpoint inhibitors in
advanced Non-Small Cell Lung Cancer (NSCLC) without actionable targets in a subset of …
advanced Non-Small Cell Lung Cancer (NSCLC) without actionable targets in a subset of …
Immunotherapeutic advances for NSCLC
M Massafra, MI Passalacqua, V Gebbia… - … : Targets and Therapy, 2021 - Taylor & Francis
Immunotherapy with antibodies against PD-1 or PD-L1, either alone or in combination with
chemotherapy, has revolutionized treatment paradigms of non-small cell lung cancer …
chemotherapy, has revolutionized treatment paradigms of non-small cell lung cancer …